Spinal cord repair in MS: Does mitochondrial metabolism play a role?

Neurology

Volumn 74, Issue 9, 2010, Pages 721-727

  Ciccarelli, O ^a   Altmann, D R ^a,b   McLean, M A ^a   Wheeler Kingshott, C A ^a   Wimpey, K ^a   Miller, D H ^a   Thompson, A J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; NERVE REGENERATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; REMYELINIZATION; SPINAL CORD;

EID: 77649252108     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d26968     Document Type: Article

References (27)

1. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615-625.
2. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256-266.
3. Ciccarelli O, Wheeler-Kingshott CA, McLean MA, et al. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 2007; 130(pt 8):2220-2231.
4. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125(pt 8):1676-1695.
5. Moffett JR, Ross B, Arun P, Madhavarao CN, Nam-boodiri AM. N-acetylaspartate in the CNS: from neurodi-agnostics to neurobiology. Prog Neurobiol 2007;81:89-131.
6. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
8. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
9. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119(pt 3):701-708.
10. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
11. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117(pt 1):49-58.
12. Mader I, Roser W, Kappos L, et al. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000;21:1220-1227.
13. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-986.
14. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11:646-651.
15. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
16. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996;7:1397-1400.
17. Blamire AM, Cader S, Lee M, Palace J, Matthews PM. Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy. Magn Reson Med 2007;58:880-885.
18. Cader S, Johansen-Berg H, Wylezinska M, et al. Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuro-image 2007;36:19-27.
19. Rovaris M, Gallo A, Falini A, et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005;62:898-902.
20. Andrews H, White K, Thomson C, et al. Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse. J Neurosci Res 2006;83: 1533-1539.
21. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132(pt 5):1161-1174.
22. Bot JC, Blezer EL, Kamphorst W, et al. The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology 2004;233:531-540.
23. Hickman SJ, Toosy AT, Jones SJ, et al. A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 2004;127(pt 11):2498-2505.
24. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383-391.
25. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007; 69:2085-2092. (Pubitemid 350175711)
26. Inglese M, Ghezzi A, Bianchi S, et al. Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. Arch Neurol 2002;59:250-255.
27. Mahad D, Lassmann H, Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuro-pathol Appl Neurobiol 2008;34:577-589.